M-A: Efficacy and safety of Selumetinib in pediatric patients with Neurofibromatosis Type 1.

Efficacy and Safety of Selumetinib in Pediatric Patients With Neurofibromatosis Type 1: A Systematic Review and Meta-analysis  – Neurology (link to abstract – $ for full-text)

Commentary: Selumetinib Significantly Decreased Tumor Burden in Children with Symptomatic Inoperable Plexiform Neurofibromas – Neurology Today

Commentary on Twitter

A study via @GreenJournal reported that #selumetinib is a safe and effective treatment for pediatric patients with symptomatic, inoperable plexiform neurofibromas, but further studies are needed to confirm long-term outcomes. https://t.co/sRVaNFPKwV#NeuroTwitter pic.twitter.com/hYJNpN1EoU

— Neurology Today (@NeurologyToday) March 11, 2022